ElastiFlow and Rohde & Schwarz Collaborate To Deliver Unmatched Network Traffic Insights
21.5.2025 16:00:00 CEST | Business Wire | Press release
ElastiFlow, a pioneer in the observability space, today announced a strategic partnership with Rohde & Schwarz, one of the world’s leading manufacturers of test and measurement, secure communications, monitoring and network testing, and broadcasting equipment. This collaboration aims to improve network visibility and data enrichment capabilities for enterprises worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521910528/en/
Network flow data, in the form of IPFIX records, is essential for understanding network traffic, detecting anomalies, and ensuring optimized performance and robust security. The new alliance leverages ElastiFlow to enrich IPFIX records from Rohde & Schwarz solutions, transforming raw data into actionable insights. This enables rapid, real-time detection of network events, security threats, and application performance issues.
The collaboration allows for deep packet inspection (DPI) technology to enhance IPFIX-based systems by providing granular, real-time analytics on application usage and user behavior. The partnership increases operational efficiency by eliminating redundancies, optimizing reporting streams, and driving deeper visibility into network performance, allowing network teams to make fast, data-driven decisions.
“We are excited to partner with ElastiFlow to bring unparalleled network traffic insights to enterprises worldwide. By combining our advanced deep packet inspection capabilities with ElastiFlow’s innovative network flow data technology, we can provide customers with a more comprehensive understanding of their network activity. This partnership underscores our commitment to delivering cutting-edge solutions that address the evolving needs of modern network visibility, and we look forward to working together to drive innovation and excellence in the industry.” Dr. Ing. Martin Mieth, Director Network Analysis for ipoque – A Rohde & Schwarz Company.
“This partnership with Rohde & Schwarz underscores ElastiFlow’s ability to integrate seamlessly with industry-leading technologies to deliver powerful, real-time network insights. Combining our enriched flow data with their deep packet inspection and network monitoring expertise enables enterprises to eliminate blind spots, optimize performance, and strengthen security. This demonstrates the trust in ElastiFlow’s solutions and our commitment to providing scalable, high-value integrations that enhance the broader network observability ecosystem.”
— Rob Cowart, Founder & CEO, ElastiFlow
Organizations or OEMs looking to enhance their data integration with innovative DPI and IPFIX technologies can visit our partner page to learn more.
About Rohde & Schwarz
Rohde & Schwarz is striving for a safer and connected world with its Test & Measurement, Technology Systems and Networks & Cybersecurity divisions. For over 90 years, the global technology group has pushed technical boundaries with developments in cutting-edge technologies. The company’s leading-edge products and solutions empower industrial, regulatory, and government customers to attain technological and digital sovereignty. The privately owned Munich-based company can act independently, long-term, and sustainably. Rohde & Schwarz generated net revenue of 2.93 billion euros in the 2023-2024 fiscal year (July to June). As of June 30, 2024, Rohde & Schwarz had more than 14,400 employees worldwide.
Additional information can be found at Rohde & Schwarz (www.rohde-schwarz.com), or connect with Rohde & Schwarz on Twitter or LinkedIn.
More information about the product can be found at ipoque – A Rohde & Schwarz Company
About ElastiFlow
ElastiFlow ensures connectivity across complex networks by providing real-time, contextualized observability for all connected services and applications. By eliminating data silos and connectivity blind spots, we enable seamless, proactive collaboration across NetOps, SecOps, and DevOps – accelerating detection and response, optimizing resources, streamlining service deployments, and delivering exceptional user experiences. Additional information can be found at ElastiFlow Inc. (www.elastiflow.com), or connect with ElastiFlow on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250521910528/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom